Sustained neuroprotection from a single intravitreal injection of PGJ2 in a nonhuman primate model of nonarteritic anterior ischemic optic neuropathy

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 11, 2014, Pages 7047-7056

  Miller, Neil R ^a,b   Johnson, Mary A ^b   Nolan, Theresa ^b   Guo, Yan ^b   Bernstein, Alexander M ^b   Bernstein, Steven L ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

15d prostaglandin J2; Anterior ischemic optic neuropathy; Intravitreal injection; Ischemia; Neuroprotection; PGJ2; White matter

Indexed keywords

PROSTAGLANDIN J2; 9-DEOXY-DELTA-9-PROSTAGLANDIN D2; ANTINEOPLASTIC AGENT; DELAYED RELEASE FORMULATION; PROSTAGLANDIN D2; PROSTAGLANDIN DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR ISCHEMIC OPTIC NEUROPATHY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ELECTRON MICROSCOPY; ELECTROPHYSIOLOGY; ELECTRORETINOGRAPHY; EVOKED VISUAL RESPONSE; EYE FUNDUS; EYE PHOTOGRAPHY; FLUORESCENCE ANGIOGRAPHY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NEUROPROTECTION; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; QUANTITATIVE ANALYSIS; RETINAL NERVE FIBER LAYER THICKNESS; RHESUS MONKEY; SINGLE DRUG DOSE; SLIT LAMP; TISSUE INJURY; TRANSMISSION ELECTRON MICROSCOPY; ANALOGS AND DERIVATIVES; ANIMAL; DELAYED RELEASE FORMULATION; DISEASE MODEL; DRUG EFFECTS; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; LONG EVANS RAT; OPTIC NERVE; OPTIC NEUROPATHY, ISCHEMIC; PATHOLOGY; PATHOPHYSIOLOGY; RAT; RETINA GANGLION CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; EVOKED POTENTIALS, VISUAL; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; INTRAVITREAL INJECTIONS; MALE; OPTIC NERVE; OPTIC NEUROPATHY, ISCHEMIC; PROSTAGLANDIN D2; PROSTAGLANDINS, SYNTHETIC; RATS; RATS, LONG-EVANS; RETINAL GANGLION CELLS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84910095800     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-14063     Document Type: Article

References (41)

1. Arnold AC. Ischemic optic neuropathy. In: Miller NR, Newman NJ, Biousse V, Kerrison JB, eds. Walsh and Hoyt's Clinical Neuro-Ophthalmology. 6th ed, Vol 1. Baltimore, MD: Lippincott- Williams & Wilkins; 2005;349-384.
2. Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy: population-based study in the State of Missouri and Los Angeles County, California. J Neuroophthalmol. 1994;14:38-44.
3. Hattenhauer MG, Leavitt JA, Hodge DO, Grill R, Gray DT. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1997;123:103-107.
4. Atkins EJ, Bruce BB, Newman NJ, Biousse V. Treatment of nonarteritic anterior ischemic optic neuropathy. Surv Ophthalmol. 2010;55:47-63.
5. Bernstein SL, Guo Y, Kelman SE, Flower RW, Johnson MA. Functional and cellular responses in a novel rodent model of anterior ischemic optic neuropathy. Invest Ophthalmol Vis Sci. 2003;44:4153-4162.
6. Goldenberg-Cohen N, Guo Y, Margolis F, Cohen Y, Miller NR, Bernstein SL. Oligodendrocyte dysfunction after induction of experimental anterior optic nerve ischemia. Invest Ophthalmol Vis Sci. 2005;46:2716-2725.
7. Bernstein SL, Guo Y, Slater BJ, Puche A, Kelman SE. Neuron stress and loss following rodent anterior ischemic optic neuropathy in double-reporter transgenic mice. Invest Ophthalmol Vis Sci. 2007;48:2304-2310.
8. Chen CS, Johnson MA, Flower RA, Slater BJ, Miller NR, Bernstein SL. A primate model of nonarteritic anterior ischemic optic neuropathy. Invest Ophthalmol Vis Sci. 2008; 49:2985-2992.
9. Lin TN, Cheung WM, Wu JS, et al. 15d-prostaglandin J2 protects brain from ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol. 2006;26:481-487.
10. Nicholson JD, Puche AC, Guo Y, Weinreich D, Slater BJ, Bernstein SL. PGJ2 provides prolonged CNS stroke protection by reducing white matter edema. PLoS One. 2012;7:1-13.
11. Straus DS, Pascual G, Li M, et al. 15-deoxy-delta 12,14- prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A. 2000;97:4844- 4849.
12. Ridder DA, Schwaninger M. NF-kappaB signalling in cerebral ischemia. Neuroscience. 2009;158:995-1006.
13. Zhao X, Zhang Y, Strong R, Grotta JC, Aronowski J. 15d- Prostaglandin J2 activates peroxisome proliferator-activated receptor-gamma, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats. J Cereb Blood Flow Metab. 2006;26:811-820.
14. Fong WH, Tsai HD, Chen YC, Wu JS, Lin TS. Anti-apoptotic actions of PPAR-gamma against ischemic stroke. Mol Neurobiol. 2010;41:180-186.
15. 2 in a rodent model of anterior ischemic optic neuropathy. Invest Ophthalmol Vis Sci. 2013;54:7402-7409.
16. Bernstein SL, Guo Y, Peterson K, Wistow G. Expressed sequence tag analysis of adult human optic nerve for NEIBank: identification of cell type and tissue markers. BMC Neurosci. 2009;10:121.
17. Mäkelä K, Hartikainen K, Rorarius M, Jäntti V. Suppression of F-VEP during isoflurane-induced EEG suppression. Electroencephalogr Clin Neurophysiol. 1996;100:269-272.
18. Johnson MA, Slater BJ, Miller NR, Bernstein SL, Flower RW. A simple integrated system for electrophysiologic recording in animals. Doc Ophthalmol. 2009;119:9-12.
19. Bach M, Halina M, Holder GE. Standard for pattern electroretinography: International Society for Clinical Electrophysiology of Vision. Doc Ophthalmol. 2000;101:11-18.
20. Marmor MF, Holder GE, Seeliger MW, Yamamoto S. Standard for clinical electroretinography. Doc Ophthalmol. 2004;108: 107-114.
21. Severns ML, Johnson MA, Bresnick GH. Methodological dependence of electroretinogram oscillatory potential amplitudes. Doc Ophthalmol. 1994;86:23-31.
22. Li C, Yang S, Chen L, et al. Stereological methods for estimating the myelin sheaths of the myelinated fibers in white matter. Anat Rec. 2009;292:1648-1655.
23. Kaplan S, Geuna S, Ronchi G, Ulkay MB, von Bartheld CS. Calibration of the stereological estimation of the number of myelinated axons in the rat scientific nerve: a multicenter study. J Neurosci Methods. 2010;187:90-99.
24. Cull GA, Reynaud J, Wang L, Cioffi GA, Burgoyne CF, Fortune B. Relationship between orbital optic nerve axons counts and retinal nerve fiber layer thickness measured by spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2012;53:7766-7773.
25. Tesser RA, Niendorf ER, Levin LA. The morphology of an infarct in nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2003;110:2013-2035.
26. Salgado C, Vilson F, Miller NR, Bernstein SL. Cellular inflammation in nonarteritic anterior ischemic optic neuropathy and its primate model. Arch Ophthalmol. 2011;129: 1583-1591.
27. Bellusci C, Savini G, Caronelli M, Carelli V, Sadun AA, Barboni P. Retinal nerve fiber layer thickness in nonarteritic anterior ischemic optic neuropathy: OCT characterization of the acute and resolving phases. Graefes Arch Clin Exp Ophthalmol. 2008;246:641-647.
28. Hedges TR III, Vuong LN, Gonzalez-Garcia AO, Mendoza- Santiesteban CE, Amaro-Quierza ML. Subretinal fluid from anterior ischemic optic neuropathy demonstrated by optical coherence tomography. Arch Ophthalmol. 2008;126:812- 815.
29. Zhang C, Guo Y, Miller NR, Bernstein SL. Optic nerve infarction and post-ischemic inflammation in the rodent model of anterior ischemic optic neuropathy (rNAION). Brain Res. 2009;126467-126475.
30. Scher JU, Pillinger MH. 15d-PGJ2: the anti-inflammatory prostaglandin? Clin Immunol. 2005;114:100-109.
31. Dore-Duffy P, Balabanov R, Beaumont T, Katar M. The CNS pericyte response to low oxygen: early synthesis of cyclopentenone prostaglandins of the J-series. Microvasc Res. 2005; 69:79-88.
32. Tuttolomondo A, Di Sciacca R, Di Raimondo D, Renda C, Pinto A, Licata G. Inflammation as a therapeutic target in acute ischemic stroke treatment. Curr Top Med Chem. 2009;9: 1240-1260.
33. Kucharova K, Chang Y, Boor A, Yong VW, Stallcup WB. Reduced inflammation accompanies diminished myelin damage and repair in the NG2 null mouse spinal cord. J Neuroinflammation. 2011;8:158.
34. Fitch MT, Silver J. Activated macrophages and the blood-brain barrier: inflammation after CNS injury leads to increases in putative inhibitory moleculars. Exp Neurol. 1997;148:587- 603.
35. Ogburn KD, Bottiglieri T, Wang Z, Figueiredo-Pereira ME. Prostaglandin J2 reduces catechol-O-methyltransferase activity and enhances dopamine toxicity in neuronal cells. Neurobiol Dis. 2006;22:294-301.
36. Arnaud LT, Myeku N, Figueiredo-Pereira ME. Proteasomecaspase- cathepsin sequence leading to tau pathology induced by prostaglandin J2 in neuronal cells. J Neurochem. 2009;110: 328-342.
37. Pierre SR, Lemmens MA, Figueiredo-Pereira ME. Subchronic infusion of the product of inflammation prostaglandin J2 models sporadic Parkinson's disease in mice. J Neuroinflammation. 2009;6:18.
38. Xiang Z, Lin T, Reeves SA. 15-d PGJ2 induces apoptosis of mouse oligodendrocyte precursor cells. J Neuroinflammation. 2007;4:18.
39. Do DV, Nguyen QD, Shah SM, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br J Ophthalmol. 2009;93:144-149.
40. Lopez-Galvez MI, Pastor-Jimeno JC. [Efficacy and safety of intravitreal injection of triamcinolone acetonide as treatment for diffuse diabetic macular edema]. Arch Soc Esp Oftalmol. 2009;84:547-548.
41. Kumar V, Ghosh B, Raina UK, Goel N. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. Acta Ophthalmol. 2010;88:e3. author reply e4.